Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44,162,869
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
34,725,223
-
Shares change
-
-1,888,986
-
Total reported value, excl. options
-
$148,268,893
-
Value change
-
-$6,317,081
-
Put/Call ratio
-
143%
-
Number of buys
-
34
-
Number of sells
-
22
-
Price
-
$4.27
Institutional Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q4 2023
As of 31 Dec 2023 Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) had 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 34,725,223 shares of stock of the company.
Largest 10 holders included ORBIMED ADVISORS LLC, BAKER BROS. ADVISORS LP, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Boxer Capital, LLC, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, MASSACHUSETTS FINANCIAL SERVICES CO /MA/, GEODE CAPITAL MANAGEMENT, LLC, and Sio Capital Management, LLC.
This table shows 55 institutional shareholders of the security as of 31 Dec 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.